{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:12:27Z","timestamp":1789193547652,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.ygyno.2004.08.028","type":"journal-article","created":{"date-parts":[[2004,9,30]],"date-time":"2004-09-30T15:17:41Z","timestamp":1096557461000},"page":"624-631","source":"Crossref","is-referenced-by-count":38,"title":["A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer"],"prefix":"10.1016","volume":"95","author":[{"given":"Anna","family":"Berkenblit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mezzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Cannistra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.08.028_bib1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary","volume":"329","author":"Cannistra","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2004.08.028_bib2","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.1997.15.6.2177","article-title":"Treatment of recurrent ovarian cancer: increasing options- \u201crecurrent\u201d results","volume":"15","author":"Ozols","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1200\/JCO.2002.20.5.1161","article-title":"Recurrent ovarian cancer: evidence-based treatment","volume":"20","author":"Ozols","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.2002.20.5.1158","article-title":"Is there a \u201cbest\u201d choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?","volume":"20","author":"Cannistra","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib8","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/BF00685595","article-title":"Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines","volume":"30","author":"Kelland","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib12","first-page":"S15-62","article-title":"Salvage weekly paclitaxel in recurrent ovarian cancer","volume":"24","author":"Abu-Rustum","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib14","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib15","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00686042","article-title":"Comparative effects of taxol and Taxotere on two different human carcinoma cell lines","volume":"34","author":"Garcia","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-291X(05)81474-3","article-title":"Effects of Taxotere on murine and human tumor cell lines","volume":"187","author":"Riou","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2004.08.028_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2004.08.028_bib19","series-title":"Proc. ASCO","article-title":"Preliminary results of the SCOTROC Trial: a Phase III comparison of Paclitaxel-Carboplatin (PC) and Docetaxel-Carboplatin (DC) as first-line chemotherapy for stage Ic-IV Epithelial Ovarian Cancer (EOC)","author":"Vasey","year":"2001"},{"key":"10.1016\/j.ygyno.2004.08.028_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2003.02.051","article-title":"Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer","volume":"21","author":"Vasey","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib21","series-title":"PASCO","article-title":"Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC)","author":"Vasey","year":"2002"},{"key":"10.1016\/j.ygyno.2004.08.028_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2003.04.003","article-title":"Progress in the management of gynecologic cancer: consensus summary statement","volume":"21","author":"Cannistra","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib23","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jnci\/87.9.676","article-title":"Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer","volume":"87","author":"Piccart","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2004.08.028_bib25","first-page":"837","article-title":"Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum","volume":"2","author":"Kavanagh","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2004.08.028_bib26","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/A:1008337103708","article-title":"A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study","volume":"11","author":"Katsumata","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib27","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.11687","article-title":"Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma","volume":"98","author":"Gravis","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.08.028_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clin. Trials"},{"key":"10.1016\/j.ygyno.2004.08.028_bib31","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2003.08.001","article-title":"Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum","volume":"91","author":"Markman","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib33","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdf036","article-title":"Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect","volume":"13","author":"Esmaeli","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","article-title":"Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer","volume":"109","author":"Esmaeli","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ygyno.2004.08.028_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/gyno.2000.5873","article-title":"Docetaxel extravasation causing significant delayed tissue injury","volume":"78","author":"Raley","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.08.028_bib37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0090-8258(03)00138-0","article-title":"Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin","volume":"89","author":"Berkenblit","year":"2003","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804006651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804006651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T10:27:26Z","timestamp":1549189646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804006651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0090825804006651"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.08.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}